If left untreated, gout can progress from sudden, reversible joint attacks to permanent joint destruction, disfiguring tophi, kidney stones, and chronic kidney disease. The disease moves through four stages, and damage that accumulates in the later stages is often irreversible. The question is not whether gout gets worse without treatment, but how far and how fast it advances in a given person. Most of the harm is preventable with urate-lowering therapy, which is why recognizing the trajectory matters.

The mechanism: why urate crystallizes and keeps coming back

Gout is a disease of monosodium urate crystal deposition, and its engine is sustained hyperuricemia. Uric acid is the end product of purine breakdown in humans because we lack the enzyme uricase that other mammals use to degrade it further. When serum urate rises above roughly 6.8 mg/dL, the saturation point at body temperature, urate can nucleate into needle-shaped crystals. These crystals sit silently in joints and soft tissue for years before anything is felt.

An acute flare is an inflammatory event, not a mechanical one. When crystals are released or newly form, they are recognized by the NLRP3 inflammasome inside macrophages, which triggers release of interleukin-1 beta. That cytokine cascade recruits neutrophils and produces the classic red, hot, swollen joint. The flare is self-limited because the body eventually coats crystals with proteins and resolves the inflammation. The crystal depot, however, remains.

This distinction explains the untreated trajectory. Treating a flare with anti-inflammatories suppresses the attack but does nothing to the underlying crystal burden. Only lowering serum urate below saturation allows existing crystals to dissolve slowly over months to years. Without that step, the disease recycles through flares and gradually builds structural damage. In plain terms: the fire can be put out, but the fuel keeps accumulating.

The four stages and what each one adds

Untreated gout follows a recognizable sequence, and each stage raises the ceiling on how bad things can get.

The first stage is asymptomatic hyperuricemia. Urate is elevated but no crystals have triggered inflammation. Most people in this stage never develop gout, so it is not automatically a disease state.

The second stage is the acute flare with intervals between attacks. Early on, flares may occur once every year or two and resolve within days to a couple of weeks. Between attacks the joint often feels normal, which is precisely why many people delay care. During this intercritical period, crystals continue depositing.

The third stage is intercritical and then chronic gouty arthritis. Flares become more frequent and involve more joints. The interval between attacks shortens. Low-grade inflammation can persist between flares, and joints begin to show persistent stiffness and reduced range of motion.

The fourth stage is advanced tophaceous disease, with crystal masses, joint destruction, and systemic complications. This is where the answer to "how bad can it get" becomes concrete. Tophi can erode bone, ulcerate through skin, and become infected. Kidney involvement can progress to chronic kidney disease. The damage at this stage is largely irreversible.

Timing: how the untreated course typically unfolds

The timeline below describes a common untreated pattern. Individual rates vary widely, and some people never reach the later stages. These are typical ranges, not guarantees.

Time frame Stage What is happening
Years before first flare Asymptomatic hyperuricemia Urate elevated; crystals may be depositing silently
First attack Initial flare Sudden severe monoarthritis, often the big toe
Months to a few years Intercritical gout Flares spaced apart; joints normal between attacks
Roughly 3 to 10 years untreated Chronic arthritis Flares more frequent, more joints, persistent symptoms
Roughly 10 or more years untreated Tophaceous gout Visible crystal deposits, bone erosion, deformity
Variable, often late Renal complications Stones, urate nephropathy, declining kidney function

The single most important variable is the average serum urate over time. Higher sustained urate accelerates crystal deposition and shortens the interval to each stage. Kidney function, genetics, alcohol use, and diuretic use all shift the slope.

Quantified context: how common progression is and what drives it

Progression is not universal. In longitudinal cohort studies, roughly a third of people with a first flare may not have another within several years, and some never develop chronic disease. That minority matters because it prevents overstating certainty. The professional caveat is that we cannot yet reliably predict at the first flare who will progress.

What we can say is that sustained hyperuricemia is the dominant modifiable driver. The higher the serum urate, the more likely crystals form and the faster tophi develop. Tophi generally appear only after years of untreated or undertreated disease, and they are a marker of substantial total body crystal burden. Once tophi are present, the disease is by definition advanced.

Frequency of flares also trends upward without treatment. Early flares may be annual or less; later, attacks can occur multiple times per year and involve several joints. This shortening interval is a clinical signal that the crystal burden is growing. It is one of the clearest signs that watchful waiting has stopped being reasonable.

Kidney risk is the part patients underestimate. Urate crystals can form stones in the urinary tract, and chronic hyperuricemia is associated with urate nephropathy and declining kidney function. The relationship is complex and partly confounded, but the association between gout and chronic kidney disease is well documented. This is a systemic disease, not just a painful toe.

The counterintuitive detail: flares can briefly increase when treatment starts

A genuinely counterintuitive point is that starting urate-lowering therapy can temporarily trigger flares. Rapid shifts in serum urate can destabilize existing crystal deposits, and the immune system responds. This is why clinicians typically prescribe anti-inflammatory prophylaxis when initiating urate-lowering therapy. It also means patients sometimes conclude the treatment made them worse and stop it, which is exactly the wrong move.

The second counterintuitive detail concerns the flare itself. A severe flare is intensely painful but not structurally destructive by itself. The destruction comes from chronic crystal deposition and persistent inflammation over years, not from any single attack. This reframes the goal: the priority is controlling urate long term, not merely surviving each flare. The pain is a symptom; the crystal burden is the disease.

Misconceptions that delay treatment

Several beliefs keep people from getting care, and each one lets the disease advance.

The first misconception is that gout is only a rich man's disease caused by overeating. Diet contributes, but genetics and kidney handling of urate are major determinants. Many people with gout have normal diets.

The second is that a normal urate level between flares rules gout out. Urate can fluctuate, and a level drawn during or shortly after a flare may be misleadingly low or high. Diagnosis often requires sampling joint fluid or imaging, not a single blood test.

The third is that treating flares is enough. Anti-inflammatories manage symptoms; they do not lower urate or dissolve crystals. This is the most consequential misconception because it leaves the underlying disease untreated for years.

The fourth is that tophi only happen to people who ignore their gout for decades. Tophi can appear sooner in people with very high urate, kidney impairment, or certain medications. The timeline is variable.

Warning signs that the disease is advancing

Seek medical evaluation promptly for any of the following:

A joint that stays red, hot, and swollen for more than two weeks despite treatment, which can signal infection rather than gout. Fever with a hot joint, which requires ruling out septic arthritis. Visible lumps near joints, ears, or over the elbows, which suggest tophi. Blood in the urine, flank pain, or gravel-like particles in urine, which suggest kidney stones. Rapidly worsening kidney function on lab tests. New numbness, weakness, or loss of function in an affected limb, which can indicate nerve or structural involvement.

Practical actions and thresholds

The practical levers are well established even if exact targets are individualized.

First, get an accurate diagnosis. Joint fluid analysis showing negatively birefringent needle-shaped crystals is the reference standard. If fluid cannot be obtained, ultrasound or dual-energy CT can support the diagnosis.

Second, ask about urate-lowering therapy rather than relying on flare treatment alone. The decision to start, and the target level, depends on flare frequency, tophi, kidney function, and comorbidities. These are clinical decisions, not self-managed ones.

Third, understand the general principle behind targets. The goal of urate-lowering therapy is to bring serum urate below the saturation threshold so crystals dissolve, and many guidelines use a target below 6 mg/dL for most patients, with a lower target for those with tophi. Confirm the specific target with your clinician, since it is individualized.

Fourth, expect prophylaxis. When urate-lowering therapy begins, anti-inflammatory cover is typically used to prevent treatment-triggered flares. Do not stop therapy because of an early flare.

Fifth, address modifiable contributors with your clinician: alcohol intake, sugar-sweetened beverages, and diuretic medications that raise urate. Do not stop prescribed diuretics on your own.

Limitations: what the evidence cannot tell you

The honest limits matter. Progression rates vary so widely that no single prognosis applies to an individual at diagnosis. We lack robust tools to predict who will progress quickly and who will not. Much of the evidence on tophi and kidney outcomes comes from observational cohorts, which show association rather than proven causation in every case. The relationship between urate and kidney decline is real but entangled with other risk factors.

What is well supported is the core message: untreated gout is a progressive crystal-deposition disease, and the later stages bring irreversible structural and renal damage. The counterintuitive and clinically important corollary is that the disease can be halted and even reversed in its crystal burden with sustained urate lowering. The damage that accumulates without treatment is largely the damage that treatment prevents.